Symbols / CTSO Stock $0.62 -4.31% Cytosorbents Corporation

Healthcare • Medical Devices • United States • NCM
CTSO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: SMA 50: SMA 200:
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Dr. Phillip P. Chan M.D., Ph.D.
Exch · Country NCM · United States
Market Cap 38.94M
Enterprise Value 63.49M
Income -8.20M
Sales 37.06M
FCF (ttm) -2.07M
Book/sh 0.09
Cash/sh 0.10
Employees 129
Insider 10d
IPO Aug 08, 2006
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E
Forward P/E inf
PEG
P/S 1.05
P/B 6.60
P/C
EV/EBITDA -4.98
EV/Sales 1.71
Quick Ratio 1.42
Current Ratio 2.12
Debt/Eq 493.16
LT Debt/Eq
EPS (ttm) -0.13
EPS next Y 0.00
EPS Growth
Revenue Growth 0.90%
EPS Gr Q/Q
Rev Gr Q/Q
Earnings (next) 2026-05-13
Earnings (prior) 2026-03-25
ROA -19.44%
ROE -96.39%
ROIC
Gross Margin 71.48%
Oper. Margin -43.87%
Profit Margin -22.12%
Shs Outstand 62.80M
Shs Float 54.82M
Insider Own 15.63%
Instit Own 26.90%
Short Float 3.50%
Short Ratio 18.75
Short Interest 2.02M
52W High 1.39
vs 52W High -55.40%
52W Low 0.50
vs 52W Low 24.25%
Beta 1.48
Impl. Vol. 4.16%
Rel Volume 0.08
Avg Volume 87.07K
Volume 6.91K
Target (mean) $5.25
Tgt Median $5.00
Tgt Low $0.75
Tgt High $10.00
# Analysts 3
Recom None
Prev Close $0.65
Price $0.62
Change -4.31%
About

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; PuriFi, an advanced hemoperfusion pump for blood purification therapies; and ECOS-300CY, an ex vivo organ perfusion system to preserve or improve the health and quality of harvested solid organs to be transplanted. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus Mean price target
2. Current target Latest analyst target
3. DCF / Fair value Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.62
Low
$0.75
High
$10.00
Mean
$5.25

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-26 main D. Boral Capital Buy → Buy $10
2026-01-12 main D. Boral Capital Buy → Buy $10
2025-12-16 main D. Boral Capital Buy → Buy $10
2025-11-14 main D. Boral Capital Buy → Buy $10
2025-11-14 main HC Wainwright & Co. Neutral → Neutral $1
2025-09-16 main D. Boral Capital Buy → Buy $10
2025-08-20 main D. Boral Capital Buy → Buy $10
2025-08-08 main D. Boral Capital Buy → Buy $10
2025-07-21 main D. Boral Capital Buy → Buy $10
2025-06-25 main D. Boral Capital Buy → Buy $10
2025-05-15 main D. Boral Capital Buy → Buy $10
2025-05-15 reit HC Wainwright & Co. Neutral → Neutral $1
2025-05-02 main D. Boral Capital Buy → Buy $10
2025-04-03 reit HC Wainwright & Co. Neutral → Neutral $1
2025-04-01 main D. Boral Capital Buy → Buy $10
2025-02-25 main D. Boral Capital Buy → Buy $10
2025-01-13 main D. Boral Capital Buy → Buy $10
2025-01-03 main D. Boral Capital Buy → Buy $10
2024-11-12 main D. Boral Capital Buy → Buy $10
2024-11-11 reit HC Wainwright & Co. Neutral → Neutral $1
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-11-18 CHAN PHILLIP P Chief Executive Officer 100,000 $0.64 $64,000
2025-08-08 CAPPONI VINCENT J President 89,100 $0.00 $0
2025-08-08 CHAN PHILLIP P Chief Executive Officer 105,600 $0.00 $0
2025-08-08 DELIARGYRIS EFTHYMIOS Officer 70,000 $0.00 $0
2025-08-08 MARIANI PETER J Chief Financial Officer 71,500 $0.00 $0
2025-02-24 CAPPONI VINCENT J President 12,000 $1.13 $13,560
2025-02-24 CHAN PHILLIP P Chief Executive Officer 34,168 $1.13 $38,610
2025-02-24 SOBEL ALAN D Director 21,950 $1.13 $24,804
2025-02-24 BATOR MICHAEL G. Director 10,000 $1.13 $11,300
2025-02-24 MARIANI PETER J Chief Financial Officer 32,625 $1.13 $36,866
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
37.06
+4.12%
35.59
+14.51%
31.08
+5.88%
29.36
Operating Revenue
37.06
+4.12%
35.59
+14.51%
31.08
+5.88%
29.36
Cost Of Revenue
10.57
-1.27%
10.71
+17.26%
9.13
-34.57%
13.96
Reconciled Cost Of Revenue
10.57
-1.27%
10.71
+17.26%
9.13
-34.57%
13.96
Gross Profit
26.49
+6.45%
24.89
+13.36%
21.95
+42.52%
15.40
Operating Expense
40.73
-1.47%
41.34
-23.31%
53.90
+14.87%
46.93
Research And Development
5.08
-33.15%
7.61
-51.22%
15.59
+3.15%
15.12
Selling General And Administration
35.65
+5.67%
33.73
-11.94%
38.31
+3.15%
37.14
General And Administrative Expense
37.87
+1.98%
37.14
Other Gand A
37.87
+1.98%
37.14
Other Operating Expenses
-5.26
+1.21%
-5.33
Total Expenses
51.30
-1.43%
52.05
-17.43%
63.03
+3.53%
60.88
Operating Income
-14.24
+13.45%
-16.45
+48.50%
-31.95
-1.35%
-31.52
Total Operating Income As Reported
-14.75
+10.35%
-16.45
+48.50%
-31.95
-1.35%
-31.52
EBITDA
-4.36
+77.39%
-19.27
+30.89%
-27.88
+8.26%
-30.39
Normalized EBITDA
-13.17
+12.47%
-15.04
+49.57%
-29.83
-6.75%
-27.94
Reconciled Depreciation
1.63
-6.48%
1.74
-13.81%
2.02
+78.81%
1.13
EBIT
-5.99
+71.51%
-21.01
+29.74%
-29.90
+5.14%
-31.52
Total Unusual Items
8.81
+308.54%
-4.22
-316.75%
1.95
+179.61%
-2.45
Total Unusual Items Excluding Goodwill
8.81
+308.54%
-4.22
-316.75%
1.95
+179.61%
-2.45
Special Income Charges
-0.51
0.00
Restructuring And Mergern Acquisition
0.51
0.00
Net Income
-8.20
+60.43%
-20.72
+29.16%
-29.25
+10.87%
-32.81
Pretax Income
-8.60
+61.63%
-22.41
+25.45%
-30.06
+11.34%
-33.91
Net Non Operating Interest Income Expense
-2.61
-86.70%
-1.40
-786.05%
-0.16
-219.08%
0.13
Interest Expense Non Operating
2.61
+86.70%
1.40
+786.05%
0.16
Net Interest Income
-2.61
-86.70%
-1.40
-786.05%
-0.16
-219.08%
0.13
Interest Expense
2.61
+86.70%
1.40
+786.05%
0.16
Interest Income Non Operating
Interest Income
Other Income Expense
8.25
+281.00%
-4.56
-322.82%
2.05
+181.32%
-2.52
Other Non Operating Income Expenses
-0.56
-67.37%
-0.33
-445.20%
0.10
+243.76%
-0.07
Gain On Sale Of Security
9.32
+320.62%
-4.22
-316.75%
1.95
+179.61%
-2.45
Tax Provision
-0.40
+76.29%
-1.69
-107.81%
-0.81
+25.52%
-1.09
Tax Rate For Calcs
0.00
-37.71%
0.00
+179.47%
0.00
-15.63%
0.00
Tax Effect Of Unusual Items
0.41
+229.90%
-0.32
-705.75%
0.05
+167.17%
-0.08
Net Income Including Noncontrolling Interests
-8.20
+60.43%
-20.72
+29.16%
-29.25
+10.87%
-32.81
Net Income From Continuing Operation Net Minority Interest
-8.20
+60.43%
-20.72
+29.16%
-29.25
+10.87%
-32.81
Net Income From Continuing And Discontinued Operation
-8.20
+60.43%
-20.72
+29.16%
-29.25
+10.87%
-32.81
Net Income Continuous Operations
-8.20
+60.43%
-20.72
+29.16%
-29.25
+10.87%
-32.81
Normalized Income
-16.59
+1.30%
-16.81
+46.01%
-31.14
-2.30%
-30.44
Net Income Common Stockholders
-8.20
+60.43%
-20.72
+29.16%
-29.25
+10.87%
-32.81
Diluted EPS
-0.13
+65.79%
-0.38
+41.54%
-0.65
+12.90%
-0.75
Basic EPS
-0.13
+65.79%
-0.38
+41.54%
-0.65
+12.90%
-0.75
Basic Average Shares
62.23
+14.32%
54.43
+21.90%
44.66
+1.98%
43.79
Diluted Average Shares
62.23
+14.32%
54.43
+21.90%
44.66
+1.98%
43.79
Diluted NI Availto Com Stockholders
-8.20
+60.43%
-20.72
+29.16%
-29.25
+10.87%
-32.81
Total Other Finance Cost
0.16
+219.08%
-0.13
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
44.18
-6.73%
47.37
-10.55%
52.96
-16.25%
63.23
Current Assets
20.63
-4.49%
21.60
-14.94%
25.40
-24.77%
33.76
Cash Cash Equivalents And Short Term Investments
6.25
+90.52%
3.28
-76.79%
14.13
-36.19%
22.14
Cash And Cash Equivalents
6.25
+90.52%
3.28
-76.79%
14.13
-36.19%
22.14
Receivables
7.55
+3.14%
7.32
+20.85%
6.06
+6.92%
5.66
Accounts Receivable
7.55
+3.14%
7.32
+20.85%
6.06
+6.92%
5.66
Gross Accounts Receivable
7.71
+3.16%
7.48
+22.45%
6.11
+6.37%
5.74
Allowance For Doubtful Accounts Receivable
-0.16
-3.80%
-0.16
-218.14%
-0.05
+34.69%
-0.08
Inventory
5.28
+93.23%
2.73
-19.04%
3.38
-2.48%
3.46
Raw Materials
0.75
+31.75%
0.57
-16.89%
0.69
+11.81%
0.61
Work In Process
1.01
+101.59%
0.50
-40.04%
0.84
-34.48%
1.28
Finished Goods
3.53
+112.53%
1.66
-10.33%
1.85
+18.07%
1.57
Prepaid Assets
Restricted Cash
0.00
-100.00%
5.00
0.00
Other Current Assets
1.55
-52.49%
3.27
+78.31%
1.83
-26.28%
2.49
Total Non Current Assets
23.55
-8.62%
25.77
-6.49%
27.56
-6.49%
29.47
Net PPE
18.75
-8.61%
20.51
-7.25%
22.12
-5.28%
23.35
Gross PPE
23.89
-3.42%
24.74
-1.64%
25.15
-0.37%
25.24
Accumulated Depreciation
-5.15
-21.77%
-4.23
-39.19%
-3.04
-60.07%
-1.90
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
6.66
-4.09%
6.95
+1.13%
6.87
+6.67%
6.44
Other Properties
10.92
-5.10%
11.51
-4.54%
12.06
-4.32%
12.60
Leases
6.31
+0.40%
6.28
+0.93%
6.22
+0.38%
6.20
Goodwill And Other Intangible Assets
3.23
-13.30%
3.72
-4.75%
3.91
-11.02%
4.39
Other Intangible Assets
3.23
-13.30%
3.72
-4.75%
3.91
-11.02%
4.39
Non Current Prepaid Assets
0.02
-56.50%
0.05
+10.95%
0.05
Other Non Current Assets
1.57
+2.67%
1.53
+3.37%
1.48
-12.06%
1.69
Total Liabilities Net Minority Interest
38.28
+5.55%
36.27
+23.04%
29.48
+5.81%
27.86
Current Liabilities
9.71
-1.18%
9.82
-30.00%
14.04
+44.48%
9.71
Payables And Accrued Expenses
7.93
-1.53%
8.05
-8.37%
8.79
+8.66%
8.09
Payables
2.87
-14.10%
3.34
-12.16%
3.80
+51.73%
2.51
Accounts Payable
2.87
-14.10%
3.34
-12.16%
3.80
+51.73%
2.51
Other Payable
0.02
Current Accrued Expenses
5.06
+7.38%
4.71
-5.48%
4.99
-10.67%
5.58
Current Debt And Capital Lease Obligation
0.54
+19.43%
0.45
-84.24%
2.87
+2537.84%
0.11
Current Debt
2.50
Other Current Borrowings
2.50
Current Capital Lease Obligation
0.54
+19.43%
0.45
+21.24%
0.37
+242.98%
0.11
Current Deferred Liabilities
0.33
-51.39%
0.68
-50.54%
1.38
-8.96%
1.52
Current Deferred Revenue
0.33
-51.39%
0.68
-50.54%
1.38
-8.96%
1.52
Other Current Liabilities
0.91
+42.52%
0.64
-35.96%
0.99
Total Non Current Liabilities Net Minority Interest
28.57
+8.06%
26.44
+71.25%
15.44
-14.90%
18.14
Long Term Debt And Capital Lease Obligation
28.57
+8.06%
26.44
+71.25%
15.44
-14.90%
18.14
Long Term Debt
16.67
+19.08%
14.00
+450.40%
2.54
-49.14%
5.00
Long Term Capital Lease Obligation
11.90
-4.35%
12.44
-3.51%
12.90
-1.87%
13.14
Stockholders Equity
5.90
-46.85%
11.11
-52.70%
23.48
-33.62%
35.37
Common Stock Equity
5.90
-46.85%
11.11
-52.70%
23.48
-33.62%
35.37
Capital Stock
0.06
+14.55%
0.06
+1.40%
0.05
+24.30%
0.04
Common Stock
0.06
+14.55%
0.06
+1.40%
0.05
+24.30%
0.04
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
62.80
+13.98%
55.10
+1.09%
54.51
+24.30%
43.85
Ordinary Shares Number
62.80
+13.98%
55.10
+1.09%
54.51
+24.30%
43.85
Additional Paid In Capital
321.02
+3.29%
310.81
+1.51%
306.19
+6.69%
287.00
Retained Earnings
-312.21
-2.70%
-304.01
-7.31%
-283.29
-11.53%
-254.00
Gains Losses Not Affecting Retained Earnings
-2.98
-170.01%
4.25
+703.29%
0.53
-77.27%
2.33
Other Equity Adjustments
-2.98
-170.01%
4.25
+703.29%
0.53
-77.27%
2.33
Total Equity Gross Minority Interest
5.90
-46.85%
11.11
-52.70%
23.48
-33.62%
35.37
Total Capitalization
22.57
-10.09%
25.10
-3.54%
26.02
-35.54%
40.37
Working Capital
10.93
-7.25%
11.78
+3.66%
11.36
-52.74%
24.05
Invested Capital
22.57
-10.09%
25.10
-11.99%
28.52
-29.35%
40.37
Total Debt
29.11
+8.25%
26.89
+46.85%
18.31
+0.34%
18.25
Net Debt
10.42
-2.78%
10.72
Capital Lease Obligations
12.44
-3.51%
12.90
-2.81%
13.27
+0.15%
13.25
Net Tangible Assets
2.68
-63.76%
7.39
-62.27%
19.57
-36.82%
30.98
Tangible Book Value
2.68
-63.76%
7.39
-62.27%
19.57
-36.82%
30.98
Interest Payable
0.03
+519.94%
0.01
Inventories Adjustments Allowances
-0.01
0.00
Other Inventories
-0.30
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-12.38
+14.22%
-14.43
+33.37%
-21.66
+23.30%
-28.23
Cash Flow From Continuing Operating Activities
-12.38
+14.22%
-14.43
+33.37%
-21.66
+23.30%
-28.23
Net Income From Continuing Operations
-8.20
+60.43%
-20.72
+29.16%
-29.25
+10.87%
-32.81
Depreciation Amortization Depletion
1.63
-6.48%
1.74
-13.81%
2.02
+78.81%
1.13
Depreciation
1.37
-9.28%
1.51
-25.42%
2.02
+78.81%
1.13
Amortization Cash Flow
0.26
+11.49%
0.23
Depreciation And Amortization
1.63
-6.48%
1.74
-13.81%
2.02
+78.81%
1.13
Amortization Of Intangibles
0.26
+11.49%
0.23
Other Non Cash Items
0.82
+66.67%
0.49
+1048.00%
0.04
Stock Based Compensation
2.77
-26.46%
3.76
-9.51%
4.16
+9.35%
3.80
Asset Impairment Charge
0.96
+112.92%
0.45
-33.00%
0.67
+6.83%
0.63
Operating Gains Losses
-9.32
-320.62%
4.22
+316.75%
-1.95
-175.53%
2.58
Net Foreign Currency Exchange Gain Loss
-9.32
-320.62%
4.22
+316.75%
-1.95
-179.61%
2.45
Gain Loss On Sale Of PPE
0.00
-100.00%
0.13
Change In Working Capital
-1.03
+76.48%
-4.38
-265.30%
2.65
+174.38%
-3.56
Change In Receivables
0.42
+124.59%
-1.72
-600.28%
-0.25
+80.94%
-1.29
Changes In Account Receivables
-1.29
Change In Inventory
-2.54
-608.00%
0.50
+172.82%
0.18
-80.61%
0.95
Change In Prepaid Assets
1.79
+232.47%
-1.35
-222.45%
1.10
+5076.64%
-0.02
Change In Payables And Accrued Expense
-0.71
+60.95%
-1.81
-212.48%
1.61
+149.47%
-3.25
Change In Other Current Assets
0.00
+100.00%
0.00
+2140.82%
-0.00
-100.09%
0.05
Investing Cash Flow
-0.41
+37.97%
-0.67
+28.54%
-0.94
+85.50%
-6.46
Cash Flow From Continuing Investing Activities
-0.41
+37.97%
-0.67
+28.54%
-0.94
+85.50%
-6.46
Net PPE Purchase And Sale
-0.09
+69.01%
-0.28
+47.22%
-0.54
+91.16%
-6.09
Purchase Of PPE
-0.16
+42.25%
-0.28
+47.22%
-0.54
+91.16%
-6.09
Sale Of PPE
0.08
0.00
Capital Expenditure
-0.49
+26.61%
-0.67
+28.54%
-0.94
+85.50%
-6.46
Net Intangibles Purchase And Sale
-0.33
+15.06%
-0.39
+3.30%
-0.40
-8.12%
-0.37
Purchase Of Intangibles
-0.33
+15.06%
-0.39
+3.30%
-0.40
-8.12%
-0.37
Financing Cash Flow
9.31
-0.24%
9.33
-35.53%
14.47
+191.84%
4.96
Cash Flow From Continuing Financing Activities
9.31
-0.24%
9.33
-35.53%
14.47
+191.84%
4.96
Net Issuance Payments Of Debt
2.48
-75.22%
10.00
0.00
-100.00%
5.00
Issuance Of Debt
2.48
-83.48%
15.00
0.00
-100.00%
5.00
Repayment Of Debt
0.00
+100.00%
-5.00
0.00
0.00
Long Term Debt Issuance
2.48
-83.48%
15.00
0.00
-100.00%
5.00
Long Term Debt Payments
0.00
+100.00%
-5.00
0.00
0.00
Net Long Term Debt Issuance
2.48
-75.22%
10.00
0.00
-100.00%
5.00
Net Common Stock Issuance
5.39
+2912.29%
0.18
-98.74%
14.26
+35423.68%
-0.04
Common Stock Payments
-0.04
Repurchase Of Capital Stock
-0.04
Proceeds From Stock Option Exercised
1.44
0.00
-100.00%
0.22
0.00
Net Other Financing Charges
-0.85
Changes In Cash
-3.48
+39.59%
-5.77
+28.97%
-8.12
+72.70%
-29.73
Effect Of Exchange Rate Changes
1.49
+1852.94%
-0.09
+14.80%
-0.10
+62.05%
-0.26
Beginning Cash Position
9.76
-37.47%
15.62
-34.48%
23.83
-55.72%
53.83
End Cash Position
7.77
-20.41%
9.76
-37.47%
15.62
-34.48%
23.83
Free Cash Flow
-12.87
+14.76%
-15.10
+33.17%
-22.59
+34.88%
-34.69
Interest Paid Supplemental Data
2.08
+61.40%
1.29
+242.48%
0.38
0.00
Common Stock Issuance
5.39
+2912.29%
0.18
-98.74%
14.26
Issuance Of Capital Stock
5.39
+2912.29%
0.18
-98.74%
14.26
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category